Projects CELT's Projects | Centre of Excellence for Long-acting Therapeutics- Centre of Excellence for Long-acting Therapeutics

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

CELT investigators sit on the Executive Board of LEAP and run a modelling and simulation core to support development and implementation of long-acting medicines for HIV, viral hepatitis and tuberculosis treatment and prevention.

AGILE - Clinical trial platform

The AGILE clinical trial is now complete. The platform was a new type of study designed for pandemic drug testing representing a world-first for infectious diseases – capable of testing multiple potential treatments in parallel and speeding up testing by pooling control data across patient groups.

Long-acting Therapeutics - Tandem Nano Ltd.

Supporting research on a portfolio of commercial long-acting medicine development activities happening within University of Liverpool spin-out Tandem Nano Ltd.

LONGEVITY Project The LONGEVITY logo is celtic knot that creates a cross shape is to the left of the word LONGEVITY with a small CELT underneath

LONGEVITY Project

LONGEVITY is an exciting and ambitious project. Specifically, CELT researchers are working with colleagues across the globe to develop interventions for malaria chemoprophylaxis, tuberculosis prevention and treatment of hepatitis C virus. Co-funding to establish CELT was also provided through this award.

Target exposures of rifapentine for long-acting formulations The organisation name is to the right of an illustration of a light grey dome with a spire that has a red AIDS ribbon over the top

The organisation name is to the right of an illustration of a light grey dome with a spire that has a red AIDS ribbon over the top

Target exposures of rifapentine for long-acting formulations

Our part in this research is now complete. Supporting a collaboration between CELT and Johns Hopkins University, this work served to better understand the compatibility of tuberculosis treatments with long-acting drug delivery.

An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic Disease This logo is the letters UKRI stacked with the words

An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease

Our part in this research is now complete. The drug delivery system is composed of responsive polymer nanoparticles and drug nanoparticles that form a nanocomposite, entrapping a reservoir of drug upon injection into the body. After the drug has been released the materials degrade into non-toxic components and leave the body.

SAFE-N-MEDTECH - Safety Testing In The Life Cycle Of Nanotechnology-Enabled Medical Technologies For Health

SAFE-N-MEDTECH is building an innovative open access platform to offer to companies and reference laboratories, the capabilities, knowhow, networks and services required for the development, testing, assessment, upscaling and market exploitation of nanotechnology-based Medical and Diagnosis Devices.

REFINE - Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices

REFINE has identified significant biological and technological gaps in the approval framework for nanomedicines, in Europe, and is developing and validating analytical approaches to produce a “smart cascade” based on the biodistribution and biocompatibility testing of candidate materials.

OPTIMIZE

The OPTIMIZE project is now complete. It was an international collaboration of partners with a shared ambition to optimise the delivery and use of antiretroviral drugs. CELT investigators were specifically involved in development of oral formulations of utility in simplification of adult and paediatric drug delivery.

Pharmacological Strategies to use the Levonorgestrel Implant in HIV-infected Women The NIH logo is the initialisation above the full organisation name

Pharmacological Strategies to use the Levonorgestrel Implant in HIV-infected Women

Our part in this research is now complete. The work aimed to determine the impact of pharmacogenetics and drug-drug interactions on the pharmacokinetics of contraceptives delivered via subcutaneous implants.

European Nanotechnology Characterisation Laboratory

Supporting the development of nanomedicines through to clinical studies. CELT investigators are the only UK partners in the EUNCL infrastructure and lead the assays groups on immunological and haematological characterisation of nanomedicines.

Harnessing potent next-generation diarylquinolines (DARQs) for long-acting injectable formulations to prevent and treat tuberculosis (TB) The NIH logo is the initialisation above the full organisation name

Harnessing potent next-generation diarylquinolines (DARQs) for long-acting injectable formulations to prevent and treat tuberculosis (TB)

Supporting a collaboration between CELT and Johns Hopkins University to develop long-acting injectable (LAI) formulations of next-generation diarylquinolines (DARQs) with and without possible companion agents for tuberculosis (TB) preventive therapy (TPT) and for use during the continuation phase of active TB treatment.

Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease

Supporting a collaboration between Queens University Belfast, University of Oxford and CELT investigators, this project aims to validate a drug screening pipeline platform for robust and rapid progression of drug combinations against Sars-CoV-2 through the preclinical pipeline.